Results from the Phase 1/2 Atalanta-1 trial

An innovative decentralized and automated PoC manufacturing paradigm was devised to facilitate the expeditious administration of freshly prepared autologous CAR-T therapies within a 7-day timeframe following apheresis in patients diagnosed with relapsed/refractory non-Hodgkin lymphoma (NHL).

Prof Marie José Kersten, a haematologist from UMC Amsterdam presented an update of the Atalanta-1 trial. As of the current phase, 14 participants have undergone treatment in the initial phase 1 segment of the investigation, while an additional 9 subjects have been enrolled in the subsequent phase 2 dose expansion segment.

The outcomes reveal noteworthy OR and CR rates in both the phase 1 and phase 2 components, coupled with a commendably low incidence of adverse effects. Instances of Cytokine Release Syndrome and severe immune-related events are infrequently observed. Notably, there is substantial proliferation of CAR-T cells in the bloodstream, with marginal distinctions between the 50 million and 110 million dose cohorts. The persistence of CAR-T cells is robust, and patient recruitment for the study remains ongoing.

Reference:

Kersten MJ, ASH 2023. #2113

With the educational support of: